VA
AVTX icon

VR Adviser’s Avalo Therapeutics AVTX Stock Holding History

VR Adviser’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,208
Closed -$444K – 38
2023
Q2 		$444K Buy
5,208
+1,041
+25% +$701K 0.07% 30
2023
Q1 		$1.75M Buy
+4,167
New +$3.28M 0.34% 23

Other funds holding AVTX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

VR Adviser's AVTX Position: Q3 2023 in Review

VR Adviser sold out of Avalo Therapeutics (AVTX) in Q3 2023, closing a stake of 5,208 shares — an estimated $444K sold.

VR Adviser first reported a position in AVTX in Q1 2023 and held it in 2 quarters. The position peaked at $1.75M in Q1 2023. 24 funds tracked by Wall St. Rank hold AVTX as of Q3 2023.

  • VR Adviser reported no remaining Avalo Therapeutics position as of Q3 2023 after selling out during the quarter.
  • VR Adviser sold 5,208 Avalo Therapeutics shares in Q3 2023, an estimated $444K.
  • VR Adviser first reported a position in Avalo Therapeutics in Q1 2023 and held it in 2 quarters.
  • VR Adviser's Avalo Therapeutics position peaked at $1.75M in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2023.

Based on VR Adviser's 13F filing for Q3 2023, filed 14 Nov 2023.